Stock ORGS ORGENESIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Orgenesis Inc.

Equities

ORGS

US68619K2042

Delayed Nasdaq
Other stock markets
 10:54:57 14/05/2024 pm IST 		5-day change 1st Jan Change
0.63 USD +3.45% Intraday chart for Orgenesis Inc. +18.82% +25.82%
16/04 North American Morning Briefing : Powell Comments, -2- DJ
15/04 Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
CI
North American Morning Briefing : Stocks Seen -2-
DJ
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.
CI
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.
CI
Earnings Flash (ORGS) ORGENESIS Reports Q3 Revenue $110,000
MT
Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States
CI
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.
CI
Orgenesis Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Morgenesis LLC Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors
CI
Earnings Flash (ORGS) ORGENESIS Reports Q1 Revenue $7M
MT
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.
CI
Orgenesis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
ORGENESIS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.
CI
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Earnings Flash (ORGS) ORGENESIS Posts Q4 Revenue $13.6M
MT
Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORGS Stock
  4. News Orgenesis Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW